Figure 2.

Schematic overview of the treatment course of patient 1 (a), patient 2 (b), and patient 3 (c). Gray boxes mark inpatient treatment periods. The dotted line indicates first presentation to our clinic. Dotted boxes mark uncertain information as it was not fully reported in previous medical reports.

AZA, azathioprine; BNB baricitinib; CTX, chemotherapy; IA, immunoadsorption; IVIG, intravenous immunoglobulins; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab; TAC, tacrolimus; TOF, tofacitinib.